Additionally, by combination with programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint inhibition, the nanovaccines can prevent the induction of iNKT anergy and overcome adaptive resistance at the tumor site [75]. The gene discussed is PDCD1; the disease is neoplasm.